Financial Performance - The company's operating revenue for Q1 2024 was CNY 431,322,575.83, representing a decrease of 34.65% compared to the same period last year[15]. - The net profit attributable to shareholders of the listed company was CNY 66,034,591.72, down 18.72% year-on-year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 57,166,617.62, a decrease of 31.29% compared to the previous year[15]. - In Q1 2024, the company achieved operating revenue of RMB 431.32 million, a decrease of 34.65% year-on-year; net profit attributable to shareholders was RMB 66.03 million, down 18.72% year-on-year[26]. - Net profit attributable to shareholders of the listed company fell by 18.71%, primarily due to a decline in COVID-related business revenue[42]. - The net profit excluding non-recurring gains and losses decreased by 31.28%[42]. - The total profit for the period was 63,495,903.50, compared to 83,360,612.59 in the previous year[57]. - The net profit for the period was 55,939,738.75, down from 67,743,836.57 in the previous year[57]. - Basic earnings per share for the period were 0.12, compared to 0.14 in the previous year[41]. - The company's total operating profit for Q1 2024 was RMB 64,004,346.42, down from RMB 84,505,378.51 in Q1 2023[63]. Assets and Equity - The total assets at the end of the reporting period were CNY 3,862,261,571.05, an increase of 1.48% from the end of the previous year[17]. - The equity attributable to shareholders of the listed company was CNY 2,626,037,203.18, reflecting a 2.59% increase from the previous year[17]. - The total liabilities and shareholders' equity amounted to 3,862,261,571.05, compared to 3,806,083,365.13 in the previous year[36]. - The company's total equity attributable to shareholders was 2,626,037,203.18, an increase from 2,559,840,879.62 in the previous year[36]. - The total assets of the company as of March 31, 2024, amounted to RMB 3.86 billion, compared to RMB 3.81 billion at the end of 2023[35]. Cash Flow - The net cash flow from operating activities was CNY 70,007,095.70[17]. - Net cash flow from operating activities for Q1 2024 was RMB 70,007,095.70, a significant improvement from a negative RMB 361,704,844.36 in Q1 2023[65]. - Cash and cash equivalents at the end of Q1 2024 were RMB 502,908,916.24, compared to RMB 726,160,578.88 at the end of Q1 2023[66]. - The company reported a net loss from investments of RMB 5,549,342.37 in Q1 2024, contrasting with a gain of RMB 1,718,670.02 in Q1 2023[63]. - Total cash inflow from investment activities in Q1 2024 was RMB 62,563,900.46, compared to RMB 50,247,072.08 in Q1 2023[66]. - The company’s financing activities generated a net cash inflow of RMB 35,735,837.11 in Q1 2024, compared to a net outflow of RMB 11,698,643.72 in Q1 2023[66]. Research and Development - Research and development expenses totaled CNY 84,553,036.69, which is 19.60% of operating revenue, an increase of 10.18 percentage points year-on-year[17]. - Research and development expenses increased to RMB 83,803,207.87 in Q1 2024, up 40.4% from RMB 59,637,893.36 in Q1 2023[63]. Business Operations - Non-COVID self-operated business revenue reached RMB 341.68 million in Q1 2024, representing a year-on-year growth of 43.33%[27]. - Domestic non-COVID self-operated business revenue was RMB 302.99 million, up 44.10% year-on-year, with domestic self-produced chemiluminescence business revenue at RMB 273.69 million, a 47.73% increase[28]. - As of March 31, 2024, the company’s products covered over 5,440 domestic terminal medical institutions, an increase of over 150 from the end of 2023, with coverage in over 1,180 tertiary hospitals[29]. - In Q1 2024, the company installed 418 new self-produced chemiluminescence analyzers, with 271 units in the domestic market and 147 units overseas[48]. - The company has obtained 157 domestic medical device registration certificates for chemiluminescence reagents, enhancing its product offerings in reproductive health diagnostics[48]. Operating Costs - Total operating costs for Q1 2024 were RMB 375,490,702.93, down 34.0% from RMB 567,935,779.01 in Q1 2023[63]. - Sales revenue from goods and services received cash of RMB 449,418,964.34 in Q1 2024, an increase from RMB 403,448,280.82 in Q1 2023[65].

中信证券股份有限公司 关于深圳市亚辉龙生物科技股份有限公司 部分募投项目延期的核查意见 中信证券股份有限公司（以下简称"中信证券"）为深圳市亚辉龙生物科技股 份有限公司（以下简称"公司"、"亚辉龙"）首次公开发行股票并上市的保荐人。 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号——规范运作》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》等有 关规定，对亚辉龙部分募投项目延期事项进行了核查，并发表如下核查意见： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 3 月 9 日核发的《关于同意深圳市亚辉龙生物科技股份有限公司首次公开发行股票注 册的批复》（证监许可[2021]755 号），公司向社会公众公开发行人民币普通股 （A 股）4,100 万股（每股面值人民币 1 元），并于 2021 年 5 月 17 日在上海证 券交易所科创板上市（以下简称"本次发行"）。本次发行的发行价格为 14.80 元 /股，本次发行募集资金总额 606,800,000.00 ...

公司代码：688575 公司简称：亚辉龙 深圳市亚辉龙生物科技股份有限公司 2023 年度内部控制评价报告 深圳市亚辉龙生物科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于 ...

证券代码：688575 证券简称：亚辉龙 公告编号：2024-020 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 截至2023年12月31日，募集资金账户余额为5,889,514.08元(包含累计收到的理财 收益和银行存款利息扣除银行手续费等的净额)。此外，公司使用闲置募集资金暂时 补充流动资金金额100,000,000.00元。 4 (一)实际募集资金金额及资金到账时间 根据中国证券监督管理委员会于2021年3月9日核发的《关于同意深圳市亚辉龙 生物科技股份有限公司首次公开发行股票注册的批复》（证监许可[2021]755号）， 公司向社会公众公开发行人民币普通股（A股）4,100万股（每股面值人民币1元）， 并于2021年5月17日在上海证券交易所科创板上市（以下简称"本次发行"）。本次发 行的发行价格为14.80元/股，本次发行募集资金总额606,800,000.00元，扣除公司不 含增值税的保荐及承销费以及其他发行费用后募集资金净额为541,334,440.75元。大 华会计师事务所（特殊普通合伙）已于2021年 ...

深圳市亚辉龙生物科技股份有限公司 2023 年度年审会计师履职情况评估报告 深圳市亚辉龙生物科技股份有限公司（以下简称"本公司"）聘请大华会计 师事务所（特殊普通合伙）（以下简称"大华所"）作为公司 2023 年年报审计机 构。根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事务 所管理办法》，本公司对大华所 2023 年审计过程中的履职情况进行了评估。评估 后，本公司认为大华所资质等方面合规有效，履职保持独立性，勤勉尽责，公允 表达审计意见。具体情况如下： 一、大华所基本情况 大华所成立于 1985 年，2012 年 2 月由大华会计师事务所有限公司转制为特 殊普通合伙。注册地址在北京市海淀区西四环中路 16 号院 7 号楼 1101，首席合 伙人为梁春。截至 2023 年 12 月 31 日合伙人 270 人，注册会计师 1471 人（其 中：签署过证券服务业务审计报告的注册会计师 1141 人）。大华所在国内重要城 市设立了 30 家分支机构。2022 年度业务总收入 33.27 亿元、审计业务收入 30.74 亿元、证券业务收入 13.89 亿元。 二、执业记录 （一）基本信息 项目合伙 ...

证券代码：688575 证券简称：亚辉龙 公告编号：2024-016 深圳市亚辉龙生物科技股份有限公司 每股分配比例：每 10 股派发现金红利人民币 2.73 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将 在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分配金 额不变，相应调整分配总额，并将另行公告具体调整情况。 本次利润分配方案尚需提交股东大会审议。 一、利润分配方案内容 经大华会计师事务所（特殊普通合伙）审计，截至 2023 年 12 月 31 日，公司期 末母公司可供分配利润为人民币 1,224,661,031.12 元。经董事会决议，公司 2023 年 度拟以实施权益分派股权登记日登记的总股本为基数分配利润。本次利润分配方案 如下： 公司拟向全体股东每 10 股派发现金红利人民币 2.73 元（含税）。截至 2024 年 3 月 31 日，公司总股本 568,308,500 股，以此计算合计拟派发现金红利人民币 155,148,220.50 元（含税）。本年度公司现金分红总额占合并报表实现归属于母公司 股东净利润的比例为 43 ...

证券代码：688575 证券简称：亚辉龙 公告编号：2024-013 深圳市亚辉龙生物科技股份有限公司 关于提前归还暂时补充流动资金的募集资金的公告 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"或"亚辉龙"）于 2023 年 6 月 5 日召开了第三届董事会第十四次、第三届监事会第十三次会议，审议通过了《关 于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司使用不超过人民币 10,000 万元（含本数）的闲置募集资金暂时补充流动资金，仅限用于公司的业务拓展、 日常经营等与主营业务相关的生产经营活动，使用期限为自公司董事会审议通过之日起 不超过 12 个月，在有效期内上述额度可以滚动循环使用。具体内容详见 2023 年 6 月 6 日披露于上海证券交易所官网（www.sse.com.cn）上的《关于归还前次暂时补充流动资 金的闲置募集资金并继续使用部分闲置募集资金暂时补充流动资金的公告》（公告编号： 2023-036）。 截止 2024 年 4 月 17 日，公司暂时用于补充流动资金的募集资金 10,000 万元已全 部提前归还至募集资金专户，并将募集资金归还情况通知了公司保荐机构及保荐代表人。 特 ...

Investment Rating - The report provides a first coverage rating for the company, indicating a positive outlook for its future performance in the chemical luminescence immunodiagnostic field [5]. Core Insights - The company, Shenzhen YHLO Biotech Co., Ltd., is a leading provider of in vitro diagnostic products in China, specializing in chemical luminescence immunoassay technology. It has a rich product matrix and a strong market position in autoimmune diseases, reproductive health, diabetes, and infectious diseases [5][6]. - The company has established seven major technology platforms to enhance product competitiveness, resulting in a comprehensive product lineup and a high coverage rate in top-tier hospitals [8][12]. - The domestic autoimmune diagnostic market is expected to grow significantly, driven by increasing patient numbers and the implementation of tiered medical policies [26][32]. Company Overview - Shenzhen YHLO Biotech was founded in September 2008 and officially listed on the STAR Market in May 2021. It focuses on the research, production, and sales of in vitro diagnostic instruments and reagents [5][6]. - The company has a well-structured management team with extensive experience in the in vitro diagnostic industry, which contributes to its strategic development and operational efficiency [19][12]. Financial Performance - The company has shown steady revenue growth, with a compound annual growth rate (CAGR) of 17% from 2018 to 2021. In 2022, the revenue reached 3.981 billion yuan, with a net profit of 1.012 billion yuan [22]. - For 2023, the company reported a revenue of 2.043 billion yuan, a decrease of 48.69% year-on-year, primarily due to the impact of COVID-19 on its business operations [22][23]. Market Dynamics - The global autoimmune disease market is projected to grow from $106 billion in 2017 to $176 billion by 2030, with a CAGR of 3.6%. The domestic autoimmune diagnostic market is expected to reach approximately 2.228 billion yuan in 2023, with a CAGR of around 14% from 2018 to 2023 [26][32]. - The report highlights the increasing competition in the domestic market, with local companies like YHLO Biotech gaining market share against established foreign brands [38][41]. Product Development - The company has developed a wide range of diagnostic reagents for various diseases, including autoimmune diseases, reproductive health, and diabetes, which are widely used in clinical testing [6][8]. - The report emphasizes the transition from qualitative to quantitative diagnostic methods, with chemical luminescence technology leading this trend in the market [35][38]. Regulatory Environment - The report discusses the ongoing centralized procurement initiatives in the in vitro diagnostic field, which are expected to accelerate the replacement of foreign products with domestic alternatives [41][42].

Company Overview - Yihuilong (688575) is a leading in-vitro diagnostics (IVD) company in China, specializing in the R&D, production, and sales of IVD products, including instruments and reagents based on chemiluminescence immunoassay [53] - The company's products cover various fields such as autoimmune diseases, reproductive health, liver disease, and respiratory infections, with over 66% coverage in domestic top-tier hospitals [51] - Yihuilong has expanded its presence to nearly 110 countries and regions globally, with products exported to Europe and the Americas [1] Financial Performance - Yihuilong's revenue grew from RMB 729 million in 2018 to RMB 2.043 billion in 2023, with a 5-year CAGR of 22.90% [23] - Net profit attributable to shareholders increased from RMB 38 million in 2018 to RMB 358 million in 2023, with a 5-year CAGR of 56.58% [23] - In 2023, non-COVID-19 self-produced business revenue reached RMB 1.324 billion, a YoY increase of 46.46%, with non-COVID-19 chemiluminescence business revenue growing 49.89% YoY to RMB 1.167 billion [23] R&D and Innovation - Yihuilong's R&D expenses grew at a CAGR of 45.88% from 2018 to 2022, with 570 R&D personnel accounting for 31.03% of total employees [3] - The company has established R&D centers in Japan, Changsha, and Wuhan, and acquired 52.64% equity in Bointe to enhance its immunoassay and biochemical diagnostic capabilities [3] - As of 2022, Yihuilong has obtained registration certificates for 150 chemiluminescence diagnostic projects, including 46 autoimmune disease-related projects [33] Market and Industry Insights - The Chinese IVD market is expected to reach RMB 219.8 billion by 2025, with a CAGR of 15.38% from 2020 to 2025, outpacing the overall medical device market [6] - Immunodiagnostics, the largest sub-segment of the IVD market, accounted for 25.9% of the total market in 2020, with a projected CAGR of 15%-20% in the coming years [73] - The 25-province alliance centralized procurement for IVD products is expected to benefit domestic leaders like Yihuilong, with total demand exceeding 700 million units and a total value of over RMB 10 billion [7] Competitive Advantages - Yihuilong is one of the few companies in China capable of providing chemiluminescence diagnostic products for autoimmune diseases, with 46 related diagnostic products [9] - The company has developed 28 reproductive health-related chemiluminescence diagnostic projects, including AMH and INHB, offering comprehensive solutions for fertility health management [9] - Yihuilong's overseas revenue reached RMB 1.733 billion in 2022, with non-COVID-19 self-produced business accounting for 12.15% of overseas revenue [35] Future Outlook - Yihuilong's self-produced business is expected to grow by over 30% in 2025, driven by the high base effect in 2023 and subsequent recovery [36] - The company plans to expand its local presence in key overseas markets, including Saudi Arabia, South Asia, Africa, Latin America, and the CIS region [35] - Yihuilong's valuation is projected at 28-35x PE for 2024, with a target price range of RMB 23.78-29.72, reflecting its leading position in the high-growth chemiluminescence industry [55]

证券代码：688575 证券简称：亚辉龙 公告编号：2024-012 深圳市亚辉龙生物科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 抗子宫内膜抗体（endometrial antibody ,EMAb）是一种以子宫内膜为靶抗原并引 起一系列免疫反应的自身抗体，EMAb 与子宫内膜异位症有关，主要存在于子宫内膜异 位症患者的血清或腹膜液（PF）中，靶向的抗原主要位于子宫内膜腺上皮的细胞质。EMAb 除了与异位的子宫内膜反应，也与正常子宫内膜发生免疫反应，激活补体系统，产生局 部免疫病理变化，直接影响子宫内膜腺体的功能，从而导致孕卵着床失败和(或)不育， 最终以不显性的早期流产而告终 人绒毛膜促性腺激素（Human chorionic gonadotropin，HCG）是维持早期妊娠的 关键激素，而抗人绒毛膜促性腺激素抗体（Anti human chorionic gonadotropin antibody，AHCGAb）（可简化为 AHAb）可通过免疫过程调节 HCG ...